Treatment History Characteristics Associated With Use of Isocarboxazid: A Nationwide Register-Based Study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Treatment History Characteristics Associated With Use of Isocarboxazid : A Nationwide Register-Based Study. / Holm, Magnus; Larsen, Jens Knud; Ishtiak-Ahmed, Kazi et al.

I: Journal of Clinical Psychopharmacology, Bind 42, Nr. 2, 2022, s. 154-158.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Holm M, Larsen JK, Ishtiak-Ahmed K, Speed M, Gasse C, Østergaard SD. Treatment History Characteristics Associated With Use of Isocarboxazid: A Nationwide Register-Based Study. Journal of Clinical Psychopharmacology. 2022;42(2):154-158. Epub 2022 jan. 19. doi: 10.1097/JCP.0000000000001505

Author

Holm, Magnus ; Larsen, Jens Knud ; Ishtiak-Ahmed, Kazi et al. / Treatment History Characteristics Associated With Use of Isocarboxazid : A Nationwide Register-Based Study. I: Journal of Clinical Psychopharmacology. 2022 ; Bind 42, Nr. 2. s. 154-158.

Bibtex

@article{55f7937ceae34824a5b2745c5aa7e36f,
title = "Treatment History Characteristics Associated With Use of Isocarboxazid: A Nationwide Register-Based Study",
abstract = "PURPOSE/BACKGROUND: The monoamine oxidase inhibitor isocarboxazid (Marplan) is occasionally used in the treatment of depression, but there is only little knowledge on the nature of the use of isocarboxazid in clinical practice. We aimed to identify treatment history characteristics associated with this use.METHODS/PROCEDURES: Via the nationwide Danish registers, we identified all adult incident users of isocarboxazid in the period from 2001 to 2018, as well as up to 5 matched controls using another antidepressant (matched on date of redeemed prescription, age, sex, and region of residence). The 5-year treatment history of the isocarboxazid users and the controls was assessed via the Danish registers. The association between treatment history characteristics and isocarboxazid use was examined by multivariate conditional logistic regression.FINDINGS/RESULTS: We identified 1455 isocarboxazid users and 7045 controls using another antidepressant. The following characteristics were associated with statistically significant increased likelihood of receiving isocarboxazid treatment: Prior treatment with a selective serotonin reuptake inhibitor (odds ratio [OR], 1.80 with 95% confidence interval [CI], 1.46-2.23), a serotonin-norepinephrine reuptake inhibitor (OR, 4.90; 95% CI, 4.08-5.89), a noradrenergic and specific serotonergic antidepressant (OR, 1.56; 95% CI, 1.30-1.88), a tricyclic antidepressant (OR, 5.05; 95% CI, 4.19-6.08), other antidepressants (OR, 4.74; 95% CI, 3.74-6.01), lithium (OR, 6.70; 95% CI, 5.08-8.83), an antipsychotic (OR, 1.43; 95% CI, 1.19-1.73), and each diagnosis of depression received in relation to psychiatric hospital treatment (OR, 1.31; 95% CI, 1.23-1.39). Forty percent of those initiating isocarboxazid had received treatment with drugs from 5 or more different psychopharmacological classes in the 5 preceding years.IMPLICATIONS/CONCLUSIONS: These findings suggest that isocarboxazid is typically used for treatment-resistant depression, consistent with guideline recommendations.",
keywords = "antidepressive agents, depression, depressive disorder, isocarboxazid, monoamine oxidase inhibitors, treatment-resistant",
author = "Magnus Holm and Larsen, {Jens Knud} and Kazi Ishtiak-Ahmed and Maria Speed and Christiane Gasse and {\O}stergaard, {S{\o}ren Dinesen}",
note = "Copyright {\textcopyright} Copyright {\textcopyright} 2022 Wolters Kluwer Health, Inc. All rights reserved.",
year = "2022",
doi = "10.1097/JCP.0000000000001505",
language = "English",
volume = "42",
pages = "154--158",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",
number = "2",

}

RIS

TY - JOUR

T1 - Treatment History Characteristics Associated With Use of Isocarboxazid

T2 - A Nationwide Register-Based Study

AU - Holm, Magnus

AU - Larsen, Jens Knud

AU - Ishtiak-Ahmed, Kazi

AU - Speed, Maria

AU - Gasse, Christiane

AU - Østergaard, Søren Dinesen

N1 - Copyright © Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2022

Y1 - 2022

N2 - PURPOSE/BACKGROUND: The monoamine oxidase inhibitor isocarboxazid (Marplan) is occasionally used in the treatment of depression, but there is only little knowledge on the nature of the use of isocarboxazid in clinical practice. We aimed to identify treatment history characteristics associated with this use.METHODS/PROCEDURES: Via the nationwide Danish registers, we identified all adult incident users of isocarboxazid in the period from 2001 to 2018, as well as up to 5 matched controls using another antidepressant (matched on date of redeemed prescription, age, sex, and region of residence). The 5-year treatment history of the isocarboxazid users and the controls was assessed via the Danish registers. The association between treatment history characteristics and isocarboxazid use was examined by multivariate conditional logistic regression.FINDINGS/RESULTS: We identified 1455 isocarboxazid users and 7045 controls using another antidepressant. The following characteristics were associated with statistically significant increased likelihood of receiving isocarboxazid treatment: Prior treatment with a selective serotonin reuptake inhibitor (odds ratio [OR], 1.80 with 95% confidence interval [CI], 1.46-2.23), a serotonin-norepinephrine reuptake inhibitor (OR, 4.90; 95% CI, 4.08-5.89), a noradrenergic and specific serotonergic antidepressant (OR, 1.56; 95% CI, 1.30-1.88), a tricyclic antidepressant (OR, 5.05; 95% CI, 4.19-6.08), other antidepressants (OR, 4.74; 95% CI, 3.74-6.01), lithium (OR, 6.70; 95% CI, 5.08-8.83), an antipsychotic (OR, 1.43; 95% CI, 1.19-1.73), and each diagnosis of depression received in relation to psychiatric hospital treatment (OR, 1.31; 95% CI, 1.23-1.39). Forty percent of those initiating isocarboxazid had received treatment with drugs from 5 or more different psychopharmacological classes in the 5 preceding years.IMPLICATIONS/CONCLUSIONS: These findings suggest that isocarboxazid is typically used for treatment-resistant depression, consistent with guideline recommendations.

AB - PURPOSE/BACKGROUND: The monoamine oxidase inhibitor isocarboxazid (Marplan) is occasionally used in the treatment of depression, but there is only little knowledge on the nature of the use of isocarboxazid in clinical practice. We aimed to identify treatment history characteristics associated with this use.METHODS/PROCEDURES: Via the nationwide Danish registers, we identified all adult incident users of isocarboxazid in the period from 2001 to 2018, as well as up to 5 matched controls using another antidepressant (matched on date of redeemed prescription, age, sex, and region of residence). The 5-year treatment history of the isocarboxazid users and the controls was assessed via the Danish registers. The association between treatment history characteristics and isocarboxazid use was examined by multivariate conditional logistic regression.FINDINGS/RESULTS: We identified 1455 isocarboxazid users and 7045 controls using another antidepressant. The following characteristics were associated with statistically significant increased likelihood of receiving isocarboxazid treatment: Prior treatment with a selective serotonin reuptake inhibitor (odds ratio [OR], 1.80 with 95% confidence interval [CI], 1.46-2.23), a serotonin-norepinephrine reuptake inhibitor (OR, 4.90; 95% CI, 4.08-5.89), a noradrenergic and specific serotonergic antidepressant (OR, 1.56; 95% CI, 1.30-1.88), a tricyclic antidepressant (OR, 5.05; 95% CI, 4.19-6.08), other antidepressants (OR, 4.74; 95% CI, 3.74-6.01), lithium (OR, 6.70; 95% CI, 5.08-8.83), an antipsychotic (OR, 1.43; 95% CI, 1.19-1.73), and each diagnosis of depression received in relation to psychiatric hospital treatment (OR, 1.31; 95% CI, 1.23-1.39). Forty percent of those initiating isocarboxazid had received treatment with drugs from 5 or more different psychopharmacological classes in the 5 preceding years.IMPLICATIONS/CONCLUSIONS: These findings suggest that isocarboxazid is typically used for treatment-resistant depression, consistent with guideline recommendations.

KW - antidepressive agents

KW - depression

KW - depressive disorder

KW - isocarboxazid

KW - monoamine oxidase inhibitors

KW - treatment-resistant

U2 - 10.1097/JCP.0000000000001505

DO - 10.1097/JCP.0000000000001505

M3 - Journal article

C2 - 35067519

VL - 42

SP - 154

EP - 158

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -